Cipmido 2.5mg Tablet
Prescription required
Highlights
composition with strength
Midodrine (2.5mg)
description
Treats low blood pressure effectively, reduces dizziness and fainting, suitable for orthostatic hypotension
key benefits
Treatment of Low blood pressure
side effects
Nausea, Rash, Difficulty in urination, High blood pressure while lying down, Chills
how to use
Take this medicine in the exact dose and duration as prescribed by your doctor
alcohol interaction
Unsafe
pregnancy interaction
Consult Your Doctor
lactation interaction
Consult Your Doctor
driving interaction
Caution
kidney interaction
Caution
liver interaction
Caution
Information
disclaimer
The contents and images displayed on this Platform are for informational purposes only and are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a registered medical practitioner with any questions you may have regarding a medical condition or the use of any product. Do not disregard professional medical advice or delay seeking it because of something you have read on this Platform.We intend to support, not replace, the doctor-patient relationship.
While we make every effort to ensure the information provided is accurate and up-to-date, we strongly recommend reviewing product labels, batch numbers, manufacturing and packaging details, as well as any warnings and usage instructions before using or consuming any product.
customer care details
In case of any issue, contact us
E-mail address: support@zeptonow.com
Seller Name
Geddit Convenience Private Limited
Seller Address
Geddit Convenience Private Limited, Unit 508, Sakti Statesman, 5th floor, Green Glen Layout, No.37/301/34/1, SY.NO.34, Ibblur Village, Begur Hobli, Bangalore, Karnataka-560103
Pharmacy License No.
KA-B61-283317, KA-B61-283318
Manufacturer or Marketer Name
Sun Ranbaxy
Manufacturer or Marketer Address
Cipla House Peninsula Business Park Ganpatrao Kadam Marg Lower Parel Mumbai 400013
Country of Origin
India
Shelf Life
24 months
Expires on or after
December 2026
